Last updated: February 14, 2026
Overview
NDC 00093-3093 refers to a medication manufactured by Salix Pharmaceuticals, identified as Xifaxan (rifaximin) 550 mg oral tablet. Approved by the FDA in 2004, Xifaxan is indicated primarily for traveler's diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D). Its unique mechanism, targeting gut bacteria with minimal systemic absorption, positions it as a valuable treatment in specific gastrointestinal conditions.
Market Landscape
Current Market Size and Trends
- The global gastrointestinal (GI) drugs market was valued at approximately $45 billion in 2021, with antibiotics encompassing a significant segment.
- Xifaxan's focus areas include hepatic encephalopathy (HE), IBS-D, and infectious diarrhea.
- The US accounted for approximately 40% of this market, with growing adoption driven by the prevalence of liver diseases and IBS.
Key Competitors
- Rifaximin-based drugs:
- Allegra (Ferring)
- Other generic rifaximin products
- Alternatives for HE:
- IBS-D treatments:
- About 20 drugs including eluxadoline, alosetron, and antispasmodics.
Market Penetration
- Xifaxan has achieved significant penetration in niche markets such as hepatic encephalopathy.
- As of 2022, the drug’s estimated annual revenue in the U.S. exceeded $700 million, reflecting strong prescribing patterns.
Pricing Analysis
Historical Pricing Trends
- The wholesale acquisition cost (WAC) for a 550 mg Xifaxan tablet averaged $60 to $85 in 2022.
- Treatment courses for IBS-D (two doses daily for 14 days) translate into approximately 28 tablets, costing $1,680 at $60 per tablet or $2,380 at $85 per tablet.
Insurance and Reimbursement
- Copay cards and insurance coverage reduce patient out-of-pocket expenses.
- Medicaid reimbursement rates are often lower, with negotiated discounts influencing net prices.
Generic Entry Impact
- As of mid-2022, generic rifaximin versions entered the market, exerting downward pressure on branded Xifaxan prices.
- Genomic manufacturers set generic prices around 25–50% below branded levels.
Price Projection (2023-2027)
| Year |
Estimated Price per Tablet |
Treatment Cost (28 tablets) |
Expected Market Share of Xifaxan |
Projected Revenue (USD)** |
| 2023 |
$55 - $75 |
$1,540 - $2,100 |
80% in key markets |
$560M - $830M |
| 2024 |
$50 - $70 |
$1,400 - $1,960 |
75% |
$400M - $715M |
| 2025 |
$45 - $65 |
$1,260 - $1,820 |
70% |
$350M - $665M |
| 2026 |
$40 - $60 |
$1,120 - $1,680 |
65% |
$290M - $550M |
| 2027 |
$35 - $55 |
$980 - $1,540 |
60% |
$220M - $460M |
Assumptions include increased generic competition, evolving prescription patterns, and potential new indications.
Factors Influencing Future Market and Prices
- Generic Competition: Accelerates price erosion, potentially reducing branded revenues by as much as 50-60% over five years.
- Regulatory Approvals: Expanded indications like travelers' diarrhea recurrence or Clostridioides difficile could stabilize or increase demand.
- Patent and Exclusivity: No recent patent extensions; exclusivity for new formulations or indications could influence pricing.
- Market Penetration: Entry into emerging markets may cause local price reductions but expand total volume.
Key Takeaways
- The US market for Xifaxan remains substantial despite increasing generic competition.
- Pricing is expected to decline gradually over five years, though revenue loss may be offset by volume gains.
- The drug's niche positioning ensures continued demand in hepatic encephalopathy and IBS-D, but new competitors and generics will pressure margins.
- Expanded indications could support revenue stability, provided regulatory approval is secured.
FAQs
1. How will generic rifaximin impact Xifaxan's market share?
Generics are expected to capture 50-70% of the prescription volume within 1-2 years of market entry, significantly reducing branded revenue.
2. Are there new indications that could boost demand?
Yes. Trials for recurrent traveler’s diarrhea and C. difficile infections hold potential, but regulatory approval timelines remain uncertain.
3. What are the key pricing differences between branded and generic rifaximin?
Branded Xifaxan prices hover around $60-$85 per tablet, while generics are roughly 25-50% cheaper, at $30-$45 per tablet.
4. How does insurance coverage affect patient access?
Copay assistance programs and formulary placements influence out-of-pocket costs, with broader insurance coverage correlating to higher utilization.
5. What are the main risks to price stability?
Market entry of low-cost generics, potential new competitors, and regulatory changes are primary risks that could accelerate price declines.
References
[1] IBISWorld. Gastrointestinal Drugs Market Size & Trends. 2022.
[2] IQVIA. US Prescription Drug Market Data. 2022.
[3] FDA. Xifaxan (rifaximin) Prescribing Information. 2022.
[4] EvaluatePharma. Antibiotics Market Forecast. 2022.
[5] Salix Pharmaceuticals. Annual Report 2022.
